MarketBeat
07 Nov 2026, 11:26 UTC · 1h ago
Globus Medical Q3 Earnings Call Highlights
Impact · against what's priced in
The downward revision to Globus Medical's 2026 revenue forecast is a negative catalyst as it undermines the core growth assumptions supporting the current price. While Nevro's decline was already anticipated, the combination of product launch delays and recruitment headwinds suggests a deterioration in the U.S. spine segment that the market had not fully discounted.
- GMED−0.50
Challenges what's priced in
- The price assumes
A sustained 10% U.S. spine growth rate that merely offsets the drag from other segments to hit the 3% blended path.
The price already assumes a slow 3% growth path and Nevro declines, but delayed spine product launches and lower sales recruiting efficacy directly challenge the 10% U.S. spine growth required to maintain even that modest baseline.
What GMED's price assumes · Sep 10
Search tags
